Disease relevance of Candidiasis, Chronic Mucocutaneous

• The primary drugs for the treatment of disseminated candidiasis are still amphotericin B or amphotericin B plus 5-fluorocytosine; the mainstay of therapy for chronic mucocutaneous candidiasis is amphotericin B [1].
• Autoimmune polyglandular disease type I (APECED) is an autosomal recessive autoimmune disease (MIM 240300) characterized by hypoparathyroidism, primary adrenocortical failure, and chronic mucocutaneous candidiasis [2].
• It is generally characterized by two of the three major clinical symptoms that may be present, Addison's disease and/or hypoparathyroidism and/or chronic mucocutaneous candidiasis [3].
• Yesterday's immunodeficiencies emphasized the clinical and familial associations of the syndromes and date from the 1920s (ataxia-telangiectasia, chronic mucocutaneous candidiasis), the 1930s (Wiskott-Aldrich syndrome), skipping the 1940s, but blossoming in the 15-y period from 1950 to 1965 [4].
• There are several subgroups of patients with chronic mucocutaneous candidiasis, and these can be identified by associated disorders such as autoimmune diseases, endocrinopathies, thymoma, and interstitial keratitis, as well as the distribution and severity of the Candida infections [5].

High impact information on Candidiasis, Chronic Mucocutaneous

• Oral ketoconazole is an effective treatment for chronic mucocutaneous candidiasis [6].
• Cimetidine as an immunomodulator: chronic mucocutaneous candidiasis as a model [7].
• When dithiothreitol extracts of clone P and H12 were compared by immunoblot, both quantitative and qualitative differences in reactivities were observed with antibodies specific for the Candida C3d receptor and with antiserum from a patient with chronic mucocutaneous candidiasis [8].
• Topical clotrimazole treatment of chronic mucocutaneous candidiasis [9].
• Miconazole in the treatment of chronic mucocutaneous candidiasis: a preliminary report [10].

Chemical compound and disease context of Candidiasis, Chronic Mucocutaneous

• Treatment of chronic mucocutaneous candidiasis with imidazole derivatives [11].
• Use of itraconazole in a patient with chronic mucocutaneous candidiasis [12].
• We examined the mechanisms of fluconazole resistance in a fluconazole-resistant Candida albicans isolate from a Japanese patient with chronic mucocutaneous candidiasis [13].
• Treatment of chronic mucocutaneous candidiasis with 5-fluorocytosine [14].

Anatomical context of Candidiasis, Chronic Mucocutaneous

• These results suggest that complement fixing antibodies to melanocytes are associated wih chronic mucocutaneous candidiasis but are not involved in the pathogenesis of common vitiligo [15].
• This type of APS often affects the skin in form of chronic mucocutaneous candidiasis and ectodermal dystrophies (vitiligo, alopecia, keratopathy, dystrophy of dental enamel and nails) [16].

Gene context of Candidiasis, Chronic Mucocutaneous

• Chronic mucocutaneous candidiasis. I. Altered antigen-stimulated IL-2, IL-4, IL-6 and interferon-gamma (IFN-gamma) production [17].
• Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy is a rare autosomal recessive disorder characterized by hypoparathyroidism, adrenal failure, chronic mucocutaneous candidiasis, and ectodermal dystrophies and other organ-specific autoimmune diseases [18].
• Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is an autosomal-recessive syndrome defined by two of the following conditions: chronic mucocutaneous candidiasis, hypoparathyroidism, or Addison's disease [19].
• The diagnosis APS I must be considered in children and adolescents with chronic mucocutaneous candidiasis, autoimmune adrenocortical failure or hypoparathyroidism in order to avoid fatal complications [20].
• Antimelanocyte antibodies were present in the sera of five (29%) of 17 patients with chronic mucocutaneous candidiasis [15].

Analytical, diagnostic and therapeutic context of Candidiasis, Chronic Mucocutaneous

• Twelve patients with chronic mucocutaneous candidiasis were assigned by random allocation to a 6-month course of treatment with ketoconazole or placebo in a double-blind trial [6].

References